Skip to main content

Table 3 Baseline patient demographics and clinical characteristics

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Parameter

rhPTH(1-84)

(n=134)

Conventional Therapy

(n=603)

Analysis Populationa

(N=737)

Age, mean ± SD, y

47.9±14.22

49.3±16.91

49.1±16.45

Age, category, n (%), y

 0–17

3 (2.2)

24 (4.0)

27 (3.7)

 18–39

34 (25.4)

135 (22.4)

169 (22.9)

 40–64

81 (60.4)

336 (55.7)

417 (56.6)

 ≥65

16 (11.9)

108 (17.9)

124 (16.8)

Women, n (%)

115 (85.8)

472 (78.3)

587 (79.6)

Race, white, n (%)

112 (83.6)

508 (84.2)

620 (84.1)

BMI, mean ± SD, y

 <18b

17.2±0.46

19.6±6.07

19.3±5.73

 ≥18c

31.1±9.48

29.7±7.32

30.0±7.72

Primary cause of hypoparathyroidism, n (%)

 Surgery

85 (63.4)

462 (76.6)

547 (74.2)

 Idiopathic

12 (9.0)

46 (7.6)

58 (7.9)

 Genetic and autoimmune

12 (9.0)

44 (7.3)

56 (7.6)

 Radiation

0

1 (0.2)

1 (0.1)

 Unknown/other/missing

25 (18.7)

50 (8.3)

75 (10.2)

Primary cause for thyroid surgery

 Thyroid cancer, n (%)

37 (56.1)

244 (60.7)

281 (60.0)

Duration of hypoparathyroidism, mean ± SD, yd

9.0±10.27

10.3±11.53

10.1±11.34

  1. BMI body mass index, rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aBaseline is defined as the assessment at enrollment (visit 1); 737 patients as of 30 June 2019
  3. brhPTH(1-84) n=3, conventional therapy n=22
  4. crhPTH(1-84) n=97, conventional therapy n=490
  5. drhPTH(1-84) n=110, conventional therapy n=563